Atossa Genetics Company Profile (NASDAQ:ATOS)

About Atossa Genetics (NASDAQ:ATOS)

Atossa Genetics logoAtossa Genetics Inc. is a clinical-stage pharmaceutical company focused on the development of therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The Company's leading program uses its intraductal microcatheters, which deliver pharmaceuticals through the breast ducts. It has initiated a Phase II clinical study using its microcatheters to deliver fulvestrant as a treatment of ductal carcinoma in-situ (DCIS) and breast cancer. Its second pharmaceutical program under development is Afimoxifene Topical Gel (AfTG) for the treatment and prevention of hyperplasia of the breast. It is also engaged in the process of evaluating other therapeutic candidates to treat other breast conditions, including breast cancer. Its medical devices include the ForeCYTE Breast Aspirator and the FullCYTE Breast Aspirator. These devices are intended for the collection of nipple aspirate fluid (NAF) for cytological testing at a laboratory.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Advanced Medical Equipment & Technology - NEC
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ATOS
  • CUSIP: N/A
  • Web: www.atossagenetics.com
Capitalization:
  • Market Cap: $3.32 million
  • Outstanding Shares: 7,412,000
Average Prices:
  • 50 Day Moving Avg: $0.48
  • 200 Day Moving Avg: $0.92
  • 52 Week Range: $0.34 - $4.35
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -0.18
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $0.40 per share
  • Price / Book: 0.95
Profitability:
  • EBIDTA: ($6,370,000.00)
  • Return on Equity: -161.74%
  • Return on Assets: -125.73%
Debt:
  • Current Ratio: 1.96%
  • Quick Ratio: 1.96%
Misc:
  • Average Volume: 295,527 shs.
  • Beta: 1.48
  • Short Ratio: 1.83
 
Frequently Asked Questions for Atossa Genetics (NASDAQ:ATOS)

What is Atossa Genetics' stock symbol?

Atossa Genetics trades on the NASDAQ under the ticker symbol "ATOS."

How were Atossa Genetics' earnings last quarter?

Atossa Genetics Inc. (NASDAQ:ATOS) posted its quarterly earnings results on Friday, August, 12th. The company reported ($0.05) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.07) by $0.02. View Atossa Genetics' Earnings History.

When will Atossa Genetics make its next earnings announcement?

Atossa Genetics is scheduled to release their next quarterly earnings announcement on Thursday, August, 10th 2017. View Earnings Estimates for Atossa Genetics.

Who are some of Atossa Genetics' key competitors?

Who are Atossa Genetics' key executives?

Atossa Genetics' management team includes the folowing people:

  • Steven C. Quay M.D., Ph.D., Chairman of the Board, President, Chief Executive Officer
  • Kyle Guse Esq., CPA, Chief Financial Officer, General Counsel, Secretary
  • Cindy Atha, Vice President of Sales and Marketing
  • Janet Rose Rea MSPH, Vice President - Regulatory Affairs and Quality
  • Shu-Chih Chen Ph.D., Director
  • Stephen J. Galli M.D., Independent Director
  • H. Lawrence Remmel Esq., Independent Director
  • Richard I. Steinhart CPA, Independent Director
  • Gregory L. Weaver, Independent Director

How do I buy Atossa Genetics stock?

Shares of Atossa Genetics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Atossa Genetics' stock price today?

One share of Atossa Genetics stock can currently be purchased for approximately $0.38.


MarketBeat Community Rating for Atossa Genetics (NASDAQ ATOS)
Community Ranking:  2.8 out of 5 ( )
Outperform Votes:  14 (Vote Outperform)
Underperform Votes:  11 (Vote Underperform)
Total Votes:  25
MarketBeat's community ratings are surveys of what our community members think about Atossa Genetics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Atossa Genetics (NASDAQ:ATOS) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Atossa Genetics (NASDAQ:ATOS)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History for Atossa Genetics (NASDAQ:ATOS)
Earnings by Quarter for Atossa Genetics (NASDAQ:ATOS)
Earnings History by Quarter for Atossa Genetics (NASDAQ ATOS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/10/2017N/AView Earnings Details
11/14/2016Q316($1.28)$0.07ViewN/AView Earnings Details
8/12/2016Q2($0.07)($0.05)ViewN/AView Earnings Details
5/5/2016Q116($0.07)ViewN/AView Earnings Details
11/12/2015Q315($0.11)($0.15)$2.80 million$0.77 millionViewListenView Earnings Details
8/6/2015Q215($0.12)($0.11)$2.05 million$2.69 millionViewN/AView Earnings Details
5/13/2015Q1($0.11)($0.13)$1.00 million$1.87 millionViewListenView Earnings Details
3/30/2015Q4 2014($0.11)($0.24)$0.10 million$0.49 millionViewN/AView Earnings Details
11/12/2014Q314($0.13)$76.60 million$3.40 millionViewN/AView Earnings Details
8/12/2014Q214($0.23)$0.01 millionViewN/AView Earnings Details
5/14/2014Q114($0.11)($0.10)$1.93 million$0.02 millionViewN/AView Earnings Details
3/27/2014Q4 2013($0.20)($0.15)$0.02 million$0.05 millionViewN/AView Earnings Details
11/12/2013($0.15)($0.22)ViewN/AView Earnings Details
8/14/2013Q213($0.17)$0.28 million$0.33 millionViewN/AView Earnings Details
5/15/2013Q113($0.11)($0.14)$0.52 million$0.18 millionViewN/AView Earnings Details
12/20/2012Q312($0.10)$0.10 million$0.11 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Atossa Genetics (NASDAQ:ATOS)
Current Year EPS Consensus Estimate: $-1.94 EPS
Next Year EPS Consensus Estimate: $-2.09 EPS

Dividends

Dividend History for Atossa Genetics (NASDAQ:ATOS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Atossa Genetics (NASDAQ:ATOS)
Insider Ownership Percentage: 5.60%
Institutional Ownership Percentage: 4.69%
Insider Trades by Quarter for Atossa Genetics (NASDAQ:ATOS)
Insider Trades by Quarter for Atossa Genetics (NASDAQ:ATOS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/17/2017H. Lawrence RemmelDirectorBuy2,500$0.63$1,575.00View SEC Filing  
4/1/2016H. Lawrence RemmelDirectorBuy1,500$0.33$495.00View SEC Filing  
3/9/2016Steven C QuayCEOBuy15,000$0.37$5,550.00View SEC Filing  
2/16/2016Shu-Chih ChenDirectorBuy15,000$0.53$7,950.00View SEC Filing  
1/19/2016Steven C QuayCEOBuy50,000$0.20$10,000.00View SEC Filing  
6/12/2015H. Lawrence RemmelDirectorBuy5,400$1.30$7,020.00View SEC Filing  
11/21/2013Gregory L WeaverDirectorBuy10,000$2.58$25,800.00View SEC Filing  
10/1/2013Steven C QuayCEOSell7,265$5.66$41,119.90View SEC Filing  
1/8/2013H. Lawrence RemmelDirectorBuy4,000$4.12$16,480.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Atossa Genetics (NASDAQ:ATOS)
Latest Headlines for Atossa Genetics (NASDAQ:ATOS)
Source:
DateHeadline
finance.yahoo.com logoAtossa Genetics Completes Enrollment in Endoxifen Phase 1 Study and Provides Update on Fulvestrant Microcatheter Phase 2 Study
finance.yahoo.com - July 25 at 4:02 PM
finance.yahoo.com logoAtossa Genetics Announces Warrant Exercises
finance.yahoo.com - June 30 at 4:15 PM
finance.yahoo.com logoAtossa Genetics Receives Positive Safety Committee Assessment of First Cohort Receiving Oral Formulation of Endoxifen in Phase 1 Dose Escalation Study
finance.yahoo.com - June 26 at 4:15 PM
finance.yahoo.com logoATOS: Balance Sheet Boosted by Recent Financing
finance.yahoo.com - June 6 at 3:49 PM
finance.yahoo.com logoAtossa Genetics to Present at the LD Micro Invitational on June 6, 2017
finance.yahoo.com - June 1 at 3:58 PM
finance.yahoo.com logoAtossa Genetics Completes Enrollment in Topical Arm of Endoxifen Phase 1 Study
finance.yahoo.com - May 19 at 9:22 AM
reuters.com logoBRIEF-Atossa Genetics qtrly loss per share $0.45
www.reuters.com - May 11 at 9:08 PM
streetinsider.com logoAtossa Genetics (ATOS) Anounces Second Positive Safety Committee Decision in Phase 1 Topical Endoxifen Dose Escalation Study
www.streetinsider.com - May 11 at 1:53 AM
finance.yahoo.com logoAtossa Genetics Receives Second Positive Safety Committee Decision in Phase 1 Topical Endoxifen Dose Escalation Study
finance.yahoo.com - May 10 at 9:04 AM
reuters.com logoBRIEF-Atossa Genetics receives approval from institutional review board for continuation of its fulvestrant microcatheter phase 2 study
www.reuters.com - May 9 at 8:44 PM
finance.yahoo.com logoAtossa Genetics Receives Approval from Institutional Review Board for Continuation of its Fulvestrant Microcatheter Phase 2 Study
finance.yahoo.com - May 9 at 9:06 AM
americanbankingnews.com logoAtossa Genetics (ATOS) Receives Daily Media Impact Rating of 0.44
www.americanbankingnews.com - April 29 at 9:58 AM
americanbankingnews.com logoAtossa Genetics Inc (ATOS) Short Interest Down 57.8% in April
www.americanbankingnews.com - April 29 at 7:21 AM
reuters.com logoBRIEF-Atossa receives positive interim review from safety committee in Endoxifen study
www.reuters.com - April 21 at 8:47 PM
americanbankingnews.com logoAtossa Genetics (ATOS) Receives News Sentiment Rating of 0.29
www.americanbankingnews.com - April 21 at 10:49 AM
finance.yahoo.com logoAtossa Genetics Receives Positive Interim Review From Independent Safety Committee in Phase 1 Endoxifen Dose Escalation Study
finance.yahoo.com - April 20 at 3:45 PM
americanbankingnews.com logoAtossa Genetics (ATOS) Getting Positive Press Coverage, AlphaOne Reports
www.americanbankingnews.com - April 18 at 12:16 PM
americanbankingnews.com logoAtossa Genetics (ATOS) Given Daily News Sentiment Rating of 0.31
www.americanbankingnews.com - April 14 at 5:21 PM
finance.yahoo.com logoAtossa Genetics Enrolls First Cohort of Eight Subjects in Endoxifen Study
finance.yahoo.com - April 7 at 8:13 AM
finance.yahoo.com logoAtossa Genetics Closes Public Offering
finance.yahoo.com - April 4 at 4:26 AM
us.rd.yahoo.com logoAtossa Genetics, Inc. Prices $4,000,000 Public Offering
us.rd.yahoo.com - March 29 at 3:54 PM
us.rd.yahoo.com logo3:48 am Atossa Genetics prices $4 mln public offering consisting of units, common stock and warrants
us.rd.yahoo.com - March 29 at 3:54 PM
bizjournals.com logoSeattle breast cancer company stock plummets as it seeks funding to continue operations
www.bizjournals.com - March 29 at 3:54 PM
streetinsider.com logoAtossa Genetics (ATOS) Confirms Pricing of $4M Public Offering
www.streetinsider.com - March 29 at 12:53 PM
reuters.com logoBRIEF-Atossa Genetics prices $4 mln public offering
www.reuters.com - March 29 at 12:53 PM
reuters.com logoBRIEF-Atossa Genetics files for public offering of up to 4 mln units
www.reuters.com - March 23 at 4:08 PM
finance.yahoo.com logoAtossa Genetics Opens Enrollment in Study of Endoxifen
finance.yahoo.com - March 23 at 4:08 PM
biz.yahoo.com logoATOSSA GENETICS INC Files SEC form 10-K/A, Annual Report
biz.yahoo.com - March 21 at 12:32 PM
biz.yahoo.com logoATOSSA GENETICS INC Files SEC form 10-Q/A, Quarterly Report
biz.yahoo.com - March 21 at 12:32 PM
finance.yahoo.com logoATOS: Pure Player in the Breast Care Space
finance.yahoo.com - March 17 at 4:21 PM
biz.yahoo.com logoATOSSA GENETICS INC Files SEC form 10-K, Annual Report
biz.yahoo.com - March 16 at 5:11 PM
bizjournals.com logoIPOs & Transactions Week in Review: Feb 13 - 17 / plus "Billion Dollar Questions" M&A whitepaper
www.bizjournals.com - February 20 at 3:37 PM
finance.yahoo.com logoAtossa Genetics Provides Update on its Phase 2 Study of Fulvestrant Administered with its Microcatheter
finance.yahoo.com - January 9 at 4:49 PM
finance.yahoo.com logo8:21 am Atossa Genetics transfers the site of its Phase 2 study of fulvestrant in order to facilitate faster enrollment, which co now anticipates completing by August 2017
finance.yahoo.com - January 9 at 4:49 PM
finance.yahoo.com logoAtossa Genetics to Present at the 9th Annual Biotech Showcase Conference on January 9, 2017
finance.yahoo.com - January 5 at 9:02 PM
finance.yahoo.com logoAtossa Genetics to Present at the 9th Annual LD Micro Main Event Conference on December 7, 2016
finance.yahoo.com - December 1 at 3:45 PM
finance.yahoo.com logoATOSSA GENETICS INC Financials
finance.yahoo.com - November 22 at 1:44 PM
biz.yahoo.com logoATOSSA GENETICS INC Files SEC form 10-Q, Quarterly Report
biz.yahoo.com - November 18 at 1:05 PM
biz.yahoo.com logoATOSSA GENETICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhib
biz.yahoo.com - November 18 at 1:05 PM
finance.yahoo.com logoATOS: Update on Third Quarter Financials
finance.yahoo.com - November 17 at 1:59 PM
seekingalpha.com logoAtossa Genetics' (ATOS) CEO Steven Quay on Q3 2016 Results - Earnings Call Transcript
seekingalpha.com - November 15 at 3:46 PM
biz.yahoo.com logoQ3 2016 Atossa Genetics Inc Earnings Release - After Market Close
biz.yahoo.com - November 14 at 9:52 AM
finanznachrichten.de logoATOSSA GENETICS INC
www.finanznachrichten.de - November 11 at 8:22 PM
finance.yahoo.com logoSeeThruEquity Issues Update on Atossa Genetics, Inc.
finance.yahoo.com - October 3 at 3:33 PM
biz.yahoo.com logoATOSSA GENETICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statement
biz.yahoo.com - September 3 at 9:12 AM
reuters.com logoBRIEF-Atossa prices underwritten public offering of 1,150,000 common shares
www.reuters.com - September 1 at 12:04 PM
streetinsider.com logoAtossa Genetics (ATOS) Prices 1.15M Share Common Stock Offering for Proceeds of ~$2.88M
www.streetinsider.com - September 1 at 12:04 PM

Social

Chart

Atossa Genetics (ATOS) Chart for Wednesday, July, 26, 2017

This page was last updated on 7/26/2017 by MarketBeat.com Staff